#Mpox Multi-country external #situation #report no. 63, published 24 February 2026 (#WHO, summary)

 

Highlights   

• Transmission of mpox continues in sexual networks, affecting both women and men, and in some historically endemic areas. 

- All clades of monkeypox virus (MPXV) continue to circulate. 

- Unless mpox outbreaks are rapidly contained and human-to-human transmission is interrupted, there is a risk of sustained community transmission. 

• In January 2026, 50 countries across all WHO regions reported a total of 1334 new confirmed mpox cases, including three deaths (case fatality ratio [CFR] 0.2%). 

- Of these cases, 66% were reported in the African Region. 

• Four regions observed a decline in confirmed cases in January, compared to December 2025, while the European Region reported an increase in confirmed cases.

• Twenty countries in Africa reported active transmission of mpox in the last six weeks (5 January – 15 February 2026), with 1142 confirmed cases, including four deaths (CFR 0.4%). 

- Countries reporting the highest number of cases in this period are the Democratic Republic of the Congo, Guinea, Madagascar, Liberia and Ghana. 

• One country, Comoros, and one territory, La Réunion (Overseas Department of France), have reported mpox due to clade Ib MPXV for the first time.   

• Outside Africa, reports of community transmission of clade Ib MPXV continue in France, Portugal and Spain, including in sexual networks of men who have sex with men.  

• WHO conducted a global mpox rapid risk assessment in February 2026; the overall global public health risk associated with the mpox multi-country outbreak was assessed as moderate. 

• India has reported a case of mpox with the clade Ib /IIb recombinant MPXV. 

- The strain sequenced is closely related to the first clade Ib / IIb recombinant strain reported by the United Kingdom of Great Britain and Northern Ireland in December 2025. 

- As both cases are travel-related, these case reports suggest wider transmission of the recombinant strain, implicating four countries in three WHO regions. 

(...)

Source: 

Link: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--63---24-february-2026

____

#Argentina - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

{A Coscoroba Swan. By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=179069673}

___

{A Black-Necked Swan. By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=178158764}

___

{A Fulvous Whistling Duck. By JeffreyGammon - Own work, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=158156460}

___

{A Brown-Hooded Gull. By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=179073441}

____

Contact with wild migratory birds present in the area is presumed to be the likely source of infection. Virological analysis has identified the presence of the H5 subtype of high pathogenicity avian influenza (HPAI). The determination of the neuraminidase subtype is pending in order to complete the characterisation of the pathogenic agent. Further information is provided in the epidemiological comments of the outbreak.

Source: 

Link: https://wahis.woah.org/#/in-review/7291

____

#Argentina - High pathogenicity avian #influenza #H5 viruses (Inf. with) (#poultry) - Immediate notification

 

At a heavy breeding poultry farm located in the province of Buenos Aires, an increase in mortality and the presence of clinical signs consistent with high pathogenicity avian influenza (HPAI) were observed. Given the clinical suspicion, official intervention was carried out, including a health inspection and the collection of diagnostic samples for processing. Laboratory analyses confirmed a positive result for high pathogenicity avian influenza subtype H5 (HPAI H5).

The event occured on a farm raising heavy breeding stock. On 21/02/2026, the National Service of Agri-Food Health and Quality (SENASA) received a notification concerning mortality and clinical signs consistent with high pathogenicity avian influenza (HPAI) which began on 19/02/2026, as reported by the reporting person. On 22/02/2026, the suspicion was officially addressed with the restriction of the establishment and taking of samples for official diagnosis. On 23/02/2026, the samples tested positive for HPAI H5. All the birds on the establishment will be culled. We will update the population data in subsequent follow-up reports.

Source: 

Link: https://wahis.woah.org/#/in-review/7290

____

#Report on #influenza viruses received and tested by the #Melbourne #WHO CC for #Reference and Research on #Influenza during 2024

 

Abstract

As part of its role in the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received 12,180 human influenza-positive samples during 2024. Viruses were analysed for their antigenic, genetic, and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hens’ eggs for potential use in seasonal influenza virus vaccines. During 2024, influenza A(H1N1)pdm09 and A(H3N2) viruses predominated, accounting for 33% and 42%, respectively, of all viruses received, compared to 5% for influenza B/Victoria. Of note, one influenza A(H5N1) virus was also received in 2024. The majority of A(H1N1)pdm09 (98%), A(H3N2) (88%) and influenza B (100%) viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2024. Of 4,007 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, twelve A(H1N1)pdm09 viruses and one B/Victoria virus showed highly reduced inhibition against oseltamivir or zanamivir. Of 3,294 total samples sequenced for baloxavir susceptibility, 18 of the 1,825 A(H3N2) samples were identified with genetic evidence of reduced susceptibility to baloxavir marboxil in the PA gene.

Source: 

Link: https://ojs.cdi.cdc.gov.au/index.php/cdi/article/view/3449

____

Longitudinal #assessment of functional #antibodies to a novel #influenza virus strain across age groups

 

Abstract

Newly emerging influenza virus strains pose a constant threat as they encounter a population lacking neutralizing antibodies against the new strain. However, cross-reactive non-neutralizing antibodies (nnABs) may be present and assist in mitigating disease symptoms via various effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Although nnABs to influenza virus have received more attention lately, little information is available on their age-related prevalence, steady-state levels, functional properties, and changes in these parameters over time. Using longitudinal samples from adolescents, adults, and older adults, collected before and after the 2009 swine flu pandemic, we comprehensively characterized the specificity and functionality of nnAB responses against H1N1 pandemic 2009 (H1N1pdm09) virus. Remarkably, all participants exhibited cross-reactive antibodies to this virus before having encountered it through infection or vaccination, with the highest baseline levels observed in older adults. The levels of these IgG antibodies showed a strong correlation with engagement of fragment crystallizable γ receptor IIIa (FcγRIIIa) and ADCC activity, both of which were notably lower in adolescents compared to adults and older adults. Without infection or vaccination, average amounts of H1N1pdm09-reactive antibodies remained relatively stable on population level over the 5-year study period. However, on an individual level, substantial increases and decreases occurred. H1N1pdm09 infection or vaccination significantly enhanced specific antibody levels and the FcγRIIIa-engaging capacity of these antibodies in all age groups. ADCC-mediating antibodies increased however only in adolescents, reaching the same level as observed in the adult groups. Taken together, our results demonstrate the presence of cross-reactive, non-neutralizing, functional, and boostable antibodies against a never-encountered influenza virus strain across all age groups. These antibodies can potentially contribute to protection from severe disease. Accordingly, in case of a newly emerging virus, their further enhancement by vaccination could be beneficial as an immediate protective measure before a strain-specific vaccine becomes available.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Source: 

Link: https://www.medrxiv.org/content/10.64898/2026.02.21.26346781v1

____

Evaluating #primer and #probe #mismatch tolerance in an #Influenza A #matrix gene RT #qPCR using contemporary human and zoonotic strains

 

Abstract

Background: 

Genetic drift and host-associated adaptation in influenza A viruses threaten the long-term reliability of RT-qPCR-based diagnostics, particularly when nucleotide mismatches arise within primer and probe binding regions. Conventional assay evaluations often emphasize sequence conservation but rarely assess functional mismatch tolerance across divergent subtypes and hosts. 

Methods: 

We performed an in silico evaluation of a matrix (M) gene–targeted RT-qPCR assay by aligning primer and probe binding regions against 22 H1N1 isolates and representative H3N2 and H5N1 reference strains, including recent zoonotic isolates from avian and bovine hosts. Nucleotide mismatches were identified, quantified, and mapped relative to assay components and oligonucleotide termini. Mismatch burden was summarized by subtype and assay region. 

Results: 

H1N1 isolates exhibited complete conservation across primer and probe regions. In contrast, H3N2 and H5N1 strains demonstrated subtype-specific sequence variability, with a total of eleven mismatches identified across seven non-H1N1 isolates (mean mismatch per isolate = 2.43). Probe mismatches predominated (63.6%), occurring primarily at internal positions, while primer mismatches were infrequent and largely avoided 3′ terminal nucleotides. Recent H5N1 isolates (2023–2024) shared conserved internal mismatches in the probe and forward primer, whereas a historical H5N1 isolate (2016) exhibited a distinct profile including a terminal probe mismatch. Despite this variability, mismatch patterns were consistent with preserved amplification potential. 

Conclusion: 

This study demonstrates that the evaluated influenza A M gene RT-qPCR assay exhibits inherent mismatch tolerance across human and zoonotic subtypes. By shifting diagnostic evaluation from strict sequence identity to functional resilience, our findings provide a framework for designing and maintaining robust molecular assays suitable for surveillance and pandemic preparedness amid ongoing viral evolution.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.02.23.707407v1

____

Primary bovine embryonic #fibroblasts demonstrate variable #fitness following #infection with avian influenza #H5N1 strains and are susceptible to a recently circulating human #H1N1pdm09 strain

 

ABSTRACT

The recent emergence of highly pathogenic avian influenza (HPAI) H5N1 (clade 2.3.4.4b, genotype B3.13) in dairy cattle presents substantial challenges to the agricultural sector and public health. Mechanistic studies of infection and transmission in cattle have proven difficult due to animal handling restrictions and the limited availability of established cell culture models. Primary bovine embryonic fibroblasts (BeEFs) were isolated and investigated here as a model to study influenza A virus (IAV) infection dynamics. We compared sialylation profiles, infectious virus production, viral replication, and plaque morphology in BeEFs following infection with the bovine HPAI H5N1 and an earlier 2.3.4.4b genotype (B1.1) isolated in 2022. The data presented here demonstrate increased expression of α-2,3 sialic acids compared to α-2,6 sialic acids in BeEFs, similar to sialylation profiles previously reported in bovine mammary tissue. These data also display increased viral fitness of the bovine origin HPAI H5N1 strains across bovine and avian cell lines, consistent with previous characterization in bovine mammary tissue. Furthermore, BeEFs were fully susceptible to a 2022 H1N1pdm09-like IAV strain while maintaining resistance to the 2009 H1N1pdm09 IAV as previously characterized in mammary cells. This study highlights the ongoing zoonotic adaptation of HPAI H5N1 in mammals and the potential for coinfection with select human H1N1 2009 pandemic lineage strains, enabling the potential development of reassortant strains. These data support the ability of BeEFs to serve as a complementary in vitro system for studying IAV infections in bovine hosts.

Source: 

Link: https://journals.asm.org/doi/10.1128/spectrum.03285-25

____

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness

 

Abstract

Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms. Previous studies showed no resistant virus emergence during prolonged molnupiravir treatment, with no resistant variants reported. However, these approaches were limited by genetic uniformity at passage initiation. To investigate viral population dynamics under enhanced genetic diversity, we employed mutagenic pre-treatment using 5-fluorouracil (5-FU) and favipiravir to generate diverse quasi-species populations before molnupiravir selection pressure. Viral populations were treated with stepwise increasing molnupiravir concentrations (10 μM ⟶ 25 μM ⟶ 40 μM) over ten serial passages. Viral detectability, plaque morphology, and mutation accumulation were analyzed using molecular and sequencing approaches. Only high-concentration favipiravir (1000 μM) pre-treatment maintained detectable viral RNA through ten passages under 40 μM molnupiravir, while favipiravir (500 μM) and 5-FU groups became undetectable after passage 6. Surviving populations formed extremely small plaques with markedly reduced replication capacity. Next-generation sequencing revealed extensive mutation accumulation across viral proteins, including polymerase proteins. Individual viable virus isolation was unsuccessful, and large-scale propagation could not be achieved. These findings demonstrate apparent survival rather than true resistance to molnupiravir, characterized by severely compromised viral fitness.

Source: 

Link: https://www.mdpi.com/1999-4915/18/2/273

____

#Uruguay - #Influenza A #HxNx viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

{Coscoroba Swan. By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=179069673}

___

On February 19, 2026, park rangers from the National System of Protected Areas (SNAP) reported observing two birds of the same species displaying neurological signs. They were able to access one of the animals, which subsequently died. The carcass was properly preserved and sent to the official laboratory for analysis. The emergency protocol was immediately activated. An area of 5 kilometres around the point of detection was defined. There are no commercial poultry farms within the area under analysis. The Official Veterinary Services of the departments of Maldonado and Rocha are visiting establishments in the area. The survey consists of identifying the establishment and owner; georeferencing; confirming the presence of birds (chickens/multiple species); evaluating management conditions and the existence of bird or other species mortality in the previous week. To date, 40 establishments have been visited and no clinical signs compatible with avian influenza have been observed on any of the inspected properties. Actions continue at the site.

Source: 

Link: https://wahis.woah.org/#/in-review/7281

____

The #bovine mammary #gland as a crucible for zoonotic #influenza virus emergence: Receptor-mediated #adaptation of HPAI #H5N1 clade 2.3.4.4b

 

Abstract

The recent emergence of highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b in U.S. dairy cattle marks a pivotal shift in the ecology of influenza A viruses (IAVs), signaling an unexpected expansion into a major livestock species. This review explores the molecular mechanisms underpinning this cross-species transmission, focusing on the unique sialic acid receptor landscape of the bovine mammary gland as a critical determinant. We synthesize emerging evidence that this tissue, which co-expresses both avian-type (α2,3-linked) and human-type (α2,6-linked) sialic acid receptors, functions as a novel biological crucible for viral adaptation. Within this environment, H5N1 virus faces selective pressure for hemagglutinin (HA) mutations—such as Q226L and N193D—that can alter receptor binding specificity toward human-like glycans, potentially bridging the species barrier. Recent studies confirm that bovine H5N1 virus isolates exhibit dual receptor-binding avidity and that single HA mutations are sufficient to shift binding preference to human receptors. The unprecedented mammalian spread of clade 2.3.4.4b, coupled with its capacity for reassortment and the recent case of a dairy farm worker infection, underscores an urgent zoonotic and pandemic threat. This review contextualizes the outbreak within the fundamental principles of influenza virus receptor biology and viral evolution, highlighting critical knowledge gaps that must be addressed through integrated surveillance and multidisciplinary research. Understanding the interplay between host receptor distribution and viral plasticity in this new niche is paramount for mitigating the risk of a future influenza virus pandemic emerging from the bovine reservoir.

Source: 

Link: https://link.springer.com/article/10.1007/s00705-026-06529-0

____

Hematogenous #neuroinvasion and genotype-dependent #transmission of #influenza A #H5N1 viruses in the #cat host

 

Abstract

The spillover of highly pathogenic avian influenza (HPAI) A H5N1 virus to mammalian hosts raises major concerns due to its pandemic potential. Cats are frequently affected mammals, often succumbing to systemic and neurological disease. Here, we characterized the pathogenesis and transmissibility of two H5N1 genotypes, B3.13 and D1.1, in cats. Infected cats exhibited high-level viremia and virus shedding in nasal, oral, and fecal secretions were consistently detected. The virus replicated initially in the upper respiratory tract and lungs, followed by systemic dissemination and neuroinvasion. Notably, the virus crossed the blood-brain-barrier by infecting endothelial cells, spreading to astrocytes and neurons, causing multifocal encephalitis. D1.1-virus infection caused protracted disease with lower shedding and no transmissibility, whereas B3.13 virus caused rapid onset with efficient shedding and transmission. These findings reveal critical H5N1 neuropathogenesis mechanisms and highlight mammalian transmission potential in a species with close human contact.

Competing Interest Statement

The authors have declared no competing interest.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.02.21.707182v1

____

History of Mass Transportation: The C&O class M-1 #500 Baldwin Steam Turbine Locomotive

 

By The only mark on the card is EKE. - eBay itemcard frontcard back, Public Domain, https://commons.wikimedia.org/w/index.php?curid=17618573

Source: 

Link: https://en.wikipedia.org/wiki/Baldwin_Locomotive_Works

____

The Fight between Carnival and Lent, Pieter Bruegel the Elder (1559)

 

Public Domain.

Source: 

Link: https://www.wikiart.org/en/pieter-bruegel-the-elder/the-fight-between-carnival-and-lent-1559-1

____

#Coronavirus Disease Research #References (by AMEDEO, Feb. 21 '26)

 

Antiviral Res

1. LIU Q, Tang B, Xuan X, Wang H, et al
   The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections.
   Antiviral Res. 2026 Feb 16:106367. doi: 10.1016/j.antiviral.2026.106367.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

2. KASAI M, Sakuma H, Suzuki M, Nishiyama M, et al
   Life-Threatening SARS-CoV-2-Associated Encephalopathy and Multiorgan Failure in Children, Asia and Oceania, 2022-2024.
   Emerg Infect Dis. 2026;32:169-179.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. MA Q, Yao L, Ding H, Tian W, et al
   SARS-CoV-2 Variant Specific Protective Immunity and Long-term Immune Recovery in People Living With HIV: A Retrospective Cohort Study.
   Int J Infect Dis. 2026 Feb 16:108491. doi: 10.1016/j.ijid.2026.108491.
   PubMed         Abstract available
   
   

   
   J Med Virol

4. 
   EXPRESSION OF CONCERN: Resistance-Associated Mutations to the Anti-SARS-CoV-2 Agent Nirmatrelvir: Selection Not Induction.
   J Med Virol. 2026;98:e70841.
   PubMed        
   
   
5. 
   EXPRESSION OF CONCERN: Culture and Identification of a "Deltamicron" SARS-CoV-2 in a Three Cases Cluster in Southern France.
   J Med Virol. 2026;98:e70843.
   PubMed        
   
   

   
   J Virol

6. ZHOU S, Zhao H, Zhu J, Zhou Y, et al
   Porcine epidemic diarrhea virus manipulates IMPDH-dependent nucleotide biosynthesis to facilitate replication.
   J Virol. 2026;100:e0173625.
   PubMed         Abstract available
   
   
7. WANG J, Zeng Y, Liu Y, Sun H, et al
   ALDH1L1 suppresses the replication of porcine epidemic diarrhea virus by degrading viral nucleocapsid and envelope proteins.
   J Virol. 2026;100:e0193325.
   PubMed         Abstract available
   
   

   
   Lancet Infect Dis

8. KUPPALLI K
   I worked at WHO: the USA leaving will not make America healthier.
   Lancet Infect Dis. 2026 Feb 13:S1473-3099(26)00069.
   PubMed        
   
   

   
   MMWR Morb Mortal Wkly Rep

9. SILK BJ, Prill MM, Winn AK, Patton ME, et al
   Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.
   MMWR Morb Mortal Wkly Rep. 2026;75:77-84.
   PubMed         Abstract available
   
   
10. RAYKIN J, Rochin I, Wiegand R, Soto V, et al
    COVID-19 Antiviral Prescription Receipt Among Outpatients Aged >/=65 Years - United States, June 1, 2023-September 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:69-76.
    PubMed         Abstract available
    
    

    
    Nature

11. SCHMIDT A, Alawathurage TM, David FS, Ogawa Y, et al
    Host control of persistent Epstein-Barr virus infection.
    Nature. 2026 Feb 19. doi: 10.1038/s41586-026-10274.
    PubMed         Abstract available
    
    

    
    Science

12. ZHANG H, Floyd K, Fang Z, Hoffmann FA, et al
    Mucosal vaccination in mice provides protection from diverse respiratory threats.
    Science. 2026 Feb 19:eaea1260. doi: 10.1126/science.aea1260.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Feb. 21 '26)

 

Antiviral Res

1. WRONSKI S, Obernolte H, Schaudien D, Braun A, et al
   Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice.
   Antiviral Res. 2026;247:106362.
   PubMed         Abstract available
   
   
2. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
   SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
   Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
   PubMed         Abstract available
   
   
3. RODRIGUEZ L, Hu Y, Li J, Han D, et al
   SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.
   Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339.
   PubMed         Abstract available
   
   

   
   Arch Virol

4. LIM KS, Selvan ME, Ea CK, Teo CH, et al
   CircRNA expression profiling in H1N1-infected primary human tracheobronchial epithelial cells identifies candidate immune-related circRNAs validated in A549 cells.
   Arch Virol. 2026;171:85.
   PubMed         Abstract available
   
   
5. JAMAL Z, Haider SA, Humayun F, Ali Q, et al
   Genomic surveillance of Influenza, SARS-CoV-2, and RSV in patients from Islamabad and Rawalpindi, Pakistan: a 2023-24 perspective.
   Arch Virol. 2026;171:78.
   PubMed        
   
   
6. SHILOVA NV, Yermolaeva DR, Nokel AY, Chinarev AA, et al
   Antibody-free detection of influenza viruses on a microarray to study their receptor specificity.
   Arch Virol. 2026;171:75.
   PubMed        
   
   

   
   Epidemiol Infect

7. MARQUEZ J, Garcia-Garcia D, Vigo MI, Bordehore C, et al
   Retrospective estimate of COVID-19 infections in nine Colombian cities in 2020.
   Epidemiol Infect. 2026;154:e22.
   PubMed         Abstract available
   
   

   
   J Gen Virol

8. PAN X, Shi X, Zhao L, Yan D, et al
   Amino acid mutations K54E and S154P in the neuraminidase attenuate H3N2 canine influenza virus in mice.
   J Gen Virol. 2026;107.
   PubMed         Abstract available
   
   

   
   J Infect

9. LIU K, Wang X, Huang J, Liu P, et al
   Zoonotic Threat of Novel H6N2 Avian Influenza Virus with Internal Genes Exclusively Derived from H9N2, China, 2025.
   J Infect. 2026 Feb 18:106705. doi: 10.1016/j.jinf.2026.106705.
   PubMed        
   
   

   
   J Infect Dis

10. CHAPPELL KJ, Mordant FL, Amarilla AA, Modhiran N, et al
    Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
    J Infect Dis. 2025 Nov 25:jiaf568. doi: 10.1093.
    PubMed         Abstract available
    
    
11. IGLESIAS-CABALLERO M, Mas V, Campoy A, Calvo C, et al
    Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.
    J Infect Dis. 2026;233:e409-e418.
    PubMed         Abstract available
    
    
12. HOFSINK Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, et al
    COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
    J Infect Dis. 2025 Oct 14:jiaf523. doi: 10.1093.
    PubMed         Abstract available
    
    
13. EDWARDS DL, Feldstein LR, Dalton AF, Ford ND, et al
    Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022.
    J Infect Dis. 2026;233:e352-e362.
    PubMed         Abstract available
    
    
14. LI B, Ke Y, Chen X, Martinez L, et al
    Robust COVID-19 Mortality Risk Assessment: Validation of a Two-Step Algorithm From the National COVID Cohort Collaborative.
    J Infect Dis. 2026;233:351-362.
    PubMed         Abstract available
    
    
15. OKABE H, Hashimoto K, Norito S, Ono T, et al
    Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains.
    J Infect Dis. 2026;233:334-341.
    PubMed         Abstract available
    
    

    
    J Virol

16. HAZELL NC, Reyna RA, Adam A, Bonam SR, et al
    mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models.
    J Virol. 2026 Jan 7:e0189725. doi: 10.1128/jvi.01897.
    PubMed         Abstract available
    
    
17. MASTERS PS
    Coronavirus genome packaging and nucleocapsid assembly.
    J Virol. 2026 Jan 8:e0133025. doi: 10.1128/jvi.01330.
    PubMed         Abstract available
    
    
18. ALVARADO RE, Lokugamage KG, Garvanska D, Estes LK, et al
    Key residues in SARS-CoV-2 NSP3 hypervariable region are necessary to modulate early stress granule activity.
    J Virol. 2026 Jan 14:e0200625. doi: 10.1128/jvi.02006.
    PubMed         Abstract available
    
    
19. TIEN C-F, Lin E-J, Tsai W-H, Tsai W-T, et al
    SARS-CoV-2 spike protein expression drives post-acute coagulopathy.
    J Virol. 2026 Jan 21:e0125525. doi: 10.1128/jvi.01255.
    PubMed         Abstract available
    
    
20. NAKANO T, Esaki M, Inoue A, Koike F, et al
    Impact of an amino acid deletion detected in the hemagglutinin (HA) antigenic site of swine influenza A virus field strains on HA antigenicity.
    J Virol. 2026 Feb 19:e0182025. doi: 10.1128/jvi.01820.
    PubMed         Abstract available
    
    

    
    JAMA

21. DILEK S, Rosen J, Levashkevich A, Sharfstein JM, et al
    The US Food and Drug Administration's Regulation of Mifepristone.
    JAMA. 2026 Jan 12. doi: 10.1001/jama.2025.23091.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

22. SILK BJ, Prill MM, Winn AK, Patton ME, et al
    Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:77-84.
    PubMed         Abstract available
    
    
23. RAYKIN J, Rochin I, Wiegand R, Soto V, et al
    COVID-19 Antiviral Prescription Receipt Among Outpatients Aged >/=65 Years - United States, June 1, 2023-September 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:69-76.
    PubMed         Abstract available
    
    

    
    N Engl J Med

24. RASMUSSEN SA, Jernigan DB
    Antigenic Drift and Antivaccine Shift in the 2025-2026 Influenza Season.
    N Engl J Med. 2026;394:732-735.
    PubMed        
    
    

    
    PLoS One

25. ROONEY G, Loibl C
    Scarcity mindset's positive association with using alternative financial services.
    PLoS One. 2026;21:e0339127.
    PubMed         Abstract available
    
    
26. KAKKAR M, Sharma D, Pal M, Mohapatra A, et al
    An analysis of WHO FluNet and FluID influenza surveillance data for South East Asia Region, 2015-2023.
    PLoS One. 2026;21:e0341567.
    PubMed         Abstract available
    
    
27. CHAKRABORTY A, Diwan A, Chiniga V, Arora V, et al
    Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.
    PLoS One. 2026;21:e0324811.
    PubMed         Abstract available
    
    
28. THAKUR A, Meza-Torres B, Fan X, Byford R, et al
    Prediction of COVID-19 hospitalisation, ICU admission or death following ChAdOx1 vaccination using artificial intelligence: A clinical predictive model from the English RAVEN study.
    PLoS One. 2026;21:e0336449.
    PubMed         Abstract available
    
    
29. LI J, Xie Z, Chen Y, Jin G, et al
    Trends and associations of pulmonary nodule detection rates in China, 2019-2023: A multicenter cross-sectional study based on Real-World Data.
    PLoS One. 2026;21:e0343207.
    PubMed         Abstract available
    
    
30. ROBERTSON LS
    Prayer, politics, and policy related to age-adjusted cancer, heart disease, infant mortality, and COVID-19 death Rates, U.S. states 2018-2021.
    PLoS One. 2026;21:e0343211.
    PubMed         Abstract available
    
    
31. WILLANE CT, Sylla PMDD, Thiam M, Ndiaye BM, et al
    Optimizing nutritionally adequate food basket using linear programming in Niayes Households, Senegal.
    PLoS One. 2026;21:e0343156.
    PubMed         Abstract available
    
    
32. KHEZRIMOTLAGH D, Imanpour S, Akbas E
    Reassessing the emergency department burden of influenza: A comprehensive real-world analysis using administrative data.
    PLoS One. 2026;21:e0340699.
    PubMed         Abstract available
    
    
33. CARTWRIGHT T, Metcalf L, Wadhen V
    'It is a lifeline': International cross-sectional survey of benefits, barriers and acceptability of online yoga during the COVID-19 pandemic.
    PLoS One. 2026;21:e0341852.
    PubMed         Abstract available
    
    
34. DIDRIKSSON I, Toniste D, Hultgren M, Spangfors M, et al
    Three-year functional, physical, and mental health outcomes after critical COVID-19: A prospective multicentre cohort study.
    PLoS One. 2026;21:e0341319.
    PubMed         Abstract available
    
    
35. LEONTI M, Mollica C, Spadaccini S, Casu L, et al
    Treatments for COVID-19 and acute respiratory infections are associated with gender and comorbidities in an Italian online survey.
    PLoS One. 2026;21:e0342466.
    PubMed         Abstract available
    
    
36. MCMASTER JMV, Gellersen HM, Korkki SM, Simons JS, et al
    The impact of lifestyle restrictions on memory in older adults.
    PLoS One. 2026;21:e0342458.
    PubMed         Abstract available
    
    
37. MARTINEZ-BORBA V, Rodriguez-Marquez AE, Garces-Arilla S, Peris-Baquero O, et al
    Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial.
    PLoS One. 2026;21:e0342908.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. LIU C, Zheng J, Wang Y, Beck F, et al
    Cryo-EM structure of locked spike glycoprotein from bat SARS-like coronavirus WIV1, molecular dynamics and biophysics across host range.
    Proc Natl Acad Sci U S A. 2026;123:e2516874123.
    PubMed         Abstract available
    
    

    
    Vaccine

39. SOBLE A, Koh M, Taaffe J, Procter SR, et al
    Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach.
    Vaccine. 2026;60 Suppl 2:128166.
    PubMed         Abstract available
    
    
40. CONTARINO F, Fiorilla C, Bella F, Leonforte F, et al
    Missed opportunities and co-administration patterns for influenza vaccination in older adults in Italy: a retrospective cohort study.
    Vaccine. 2026;77:128366.
    PubMed         Abstract available
    
    
41. GREEN MA, Jeffery C, Cheyne C, Bonnett L, et al
    Learning from the outliers: A longitudinal ecological study of social and spatial inequalities in older adult influenza vaccination and hospitalisation (Cheshire and Merseyside, UK, 2018-19 to 2023-24).
    Vaccine. 2026;77:128356.
    PubMed         Abstract available
    
    
42. ANDERSON SA, Smith ER, Wan Z, Amend KL, et al
    Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.
    Vaccine. 2026;75:128225.
    PubMed         Abstract available
    
    
43. SHARMA AJ, Smoots AN, Madni SA, Zauche LH, et al
    COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
    Vaccine. 2026;75:128268.
    PubMed         Abstract available
    
    
44. TONDEL C, Jenum S, Tonby K, Christensen EE, et al
    SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
    Vaccine. 2026;75:128290.
    PubMed         Abstract available
    
    
45. KENEALY T, Aguirre-Duarte N, Roxburgh RH, Royle G, et al
    Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.
    Vaccine. 2026;75:128275.
    PubMed         Abstract available
    
    
46. PARK IY, Cantu-Aldana A, Grafft N, Lo BK, et al
    Fathers' reports of within-household vaccine decision making and young children's COVID-19 vaccination status.
    Vaccine. 2026;75:128282.
    PubMed         Abstract available
    
    
47. THAKKAR K, Kefalogianni R, Zhang J, Yung CF, et al
    Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
    Vaccine. 2026;75:128285.
    PubMed         Abstract available
    
    
48. LOTSPEICH-COLE L, Jha MK, Parvathaneni S, Lee RC, et al
    Neonatal mice immune response to COVID-19 mRNA vaccine.
    Vaccine. 2026;75:128271.
    PubMed         Abstract available
    
    
49. HAHM HC, Tang M, Lupaczyk L, Lee J, et al
    Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis.
    Vaccine. 2026;75:128283.
    PubMed         Abstract available
    
    
50. BARBER C, Barber M, Lee JSW, Ting J, et al
    Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan.
    Vaccine. 2026;75:128261.
    PubMed         Abstract available
    
    
51. VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
    Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.
    Vaccine. 2026;75:128208.
    PubMed         Abstract available
    
    
52. YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
    Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
    Vaccine. 2026;75:128227.
    PubMed         Abstract available
    
    
53. YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
    Pathways to COVID-19 vaccine initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
    Vaccine. 2026;75:128253.
    PubMed         Abstract available
    
    
54. HANDY AB, Ren B, Seidman LC, Granger SW, et al
    Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
    Vaccine. 2026;75:128226.
    PubMed         Abstract available
    
    
55. FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
    Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
    Vaccine. 2026;75:128249.
    PubMed         Abstract available
    
    
56. MALTEZOU HC, Giannouchos TV, Gamaletsou MN, Koukou DM, et al
    Absenteeism related to respiratory infections among healthcare personnel in hospitals in Greece from 2020-2021 to 2024-2025.
    Vaccine. 2026;75:128264.
    PubMed         Abstract available
    
    
57. ADAM A, Lee C, Jones MC, Harrington BR, et al
    VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
    Vaccine. 2026;75:128255.
    PubMed         Abstract available
    
    
58. OKOLI GN, Kwan MYW, Chan ELY, Murphy C, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study.
    Vaccine. 2026;75:128262.
    PubMed         Abstract available
    
    
59. MANSFIELD ME, Okui L, Simon S, Hosangadi D, et al
    Understanding COVID-19 vaccination choices and development of a toolkit and training for Botswana, 2022-2023.
    Vaccine. 2026;75:128274.
    PubMed         Abstract available
    
    
60. PAXITZIS AN, Oyebanji OA, Olagunju OJ, Keresztesy D, et al
    Antibody responses to SARS-CoV-2 vaccine in nursing home residents support a Bi-annual update schedule.
    Vaccine. 2026;75:128240.
    PubMed         Abstract available
    

Amino acid #mutations K54E and S154P in the #neuraminidase attenuate #H3N2 #canine #influenza virus in mice

 

ABSTRACT

Dogs are considered mixing vessels for influenza viruses, posing a pandemic potential via viral reassortment. Our previous studies indicated that the avian-origin H3N2 canine influenza virus (A/canine/Zhejiang/1/2010, abbreviated C1) is virulent in canine and mice. Furthermore, we found that the HA and NA genes of C1 share a close genetic relationship with an H3N2 avian influenza virus (A/duck/Shanghai/06/2009, abbreviated D6), but they exhibit distinct pathogenicity. However, the understanding mechanisms remain unclear. In the present study, we explored the genetic determinants that contribute to the different pathogenicity between the C1 and D6. By using the reverse genetics approaches, we rescued several single-gene and position-substituted reassortant viruses based on the C1. The replication in Madin–Darby canine kidney cells and pathogenic trial in mice showed that the neuraminidase (NA) gene played a critical role in C1 virulence. Further analysis demonstrated that the K54E and S154P mutations in NA significantly reduced NA enzymatic activity, impairing viral release from infected cells. Consequently, these mutant viruses lost their ability to infect mice. Overall, our findings identify two novel virulence determinants in NA and elucidate the mechanisms behind the distinct pathogenicity between the C1 and D6 in mice. These results may provide some new targets for H3N2 influenza virus vaccines and antiviral drug development.

Source: 

Link: https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.002223

____

History of Mass Transportation: A First-generation GTEL and a 1923 electric auto in Fremont, Nebraska in 1953

By Union Pacific Railroad - eBay itemphoto frontphoto back, Public Domain, https://commons.wikimedia.org/w/index.php?curid=22868545

Source: 

Link: https://en.wikipedia.org/wiki/Gas-turbine_locomotive

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, Feb. 20 '26)

 

{Excerpt}

Time Period: February 08, 2026 - February 14, 2026

-- H5 Detection: 9 site(s) (1.9%)

-- No Detection: 466 site(s) (98.1%)

-- No samples in last week: 171 site(s)

The H5 detections at sewershed IDs 809 and 912 in Michigan are false detections resulting from a data error. These will be corrected in the next update.

(...)

Source: 

Link: https://www.cdc.gov/nwss/rv/wwd-h5.html

____

#India - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 

Poultry farms in Andhra Pradesh State.

Source: 

Link: https://wahis.woah.org/#/in-review/7268

____

#India - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

{By Pkspks - Own work, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=162556362}

___

More than 300 House Crows in Bihar: Darbhanga, Patna, Bhagalpur, Katihar, Pashchim Champaran Regions. 

Source: 

Link: https://wahis.woah.org/#/in-review/7269

____